Efficacy and safety of relacorilant for the treatment of patients with Cushing’s syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

Pivonello R, Arnaldi G, Auchus RJ, Badiu C, Busch RS, Cannavò S, Dischinger U, Dobri GA, Donegan DM, Elenkova A, Fazeli PK, Feelders RA, Garcia-Centeno R, Gilis-Januszewska A, Hamidi O, Hannoush ZC, Kargi AY, Miller HJ, Ranetti AE, Recasens M, Reincke M, Rovner S, Salvatori R, Silverstein J, Stigliano A, Terzolo M, Wang C, Yuen KCJ, Kesner-Hays A, Hand AL, Tudor IC, Araque KA, Moraitis AG; GRACE Study Investigators. Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. Lancet Diabetes Endocrinol. 2026 Feb 20:S2213-8587(25)00362-6. doi: 10.1016/S2213-8587(25)00362-6. Epub ahead of print. PMID: 41730814.


Related Posts

Stephanie Smooke Praw, MD Appointed Interim Chief of the UCLA Division of Endocrinology featured image